Cargando…

Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?

Detalles Bibliográficos
Autores principales:	Msaouel, Pavlos, Carugo, Alessandro, Genovese, Giannicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592295/ https://www.ncbi.nlm.nih.gov/pubmed/31258836 http://dx.doi.org/10.18632/oncotarget.26970

Ejemplares similares

SMARCB1 regulates the hypoxic stress response in sickle cell trait
por: Soeung, Melinda, et al.
Publicado: (2023)

Targeting proteostasis maintenance and autophagy in senescence
por: L’Hôte, Valentin, et al.
Publicado: (2022)

Special Issue on “Proteostasis and Autophagy”
por: Kern, Andreas, et al.
Publicado: (2019)

Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye
por: Msaouel, Pavlos, et al.
Publicado: (2020)

SMARCB1(INI1)-deficient Sinonasal Basaloid Carcinoma: A Novel Member of the Expanding Family of SMARCB1-deficient Neoplasms
por: Agaimy, Abbas, et al.
Publicado: (2014)

SMARCB1/INI1-deficient tumors of adulthood
por: Parker, Nathaniel A., et al.
Publicado: (2020)

Where Next?
Publicado: (1897)

Oncogenic roles of SMARCB1/INI1 and its deficient tumors
por: Kohashi, Kenichi, et al.
Publicado: (2017)

SMARCB1(INI-1)-Deficient Sinonasal Carcinoma: An Evolving Entity
por: Chung, Sei Y., et al.
Publicado: (2023)

Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
por: Ngo, Carine, et al.
Publicado: (2022)

SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities
por: Cooper, Garrett W., et al.
Publicado: (2022)

SMARCB1-Deficient Sinonasal Carcinoma: Case Report and Review of the Literature
por: AlMadan, Nasser M., et al.
Publicado: (2023)

Gene of the month: SMARCB1
por: Kalimuthu, Sangeetha N, et al.
Publicado: (2016)

Cancer Genetics and Therapeutic Opportunities in Urologic Practice
por: Adashek, Jacob J., et al.
Publicado: (2020)

Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms
por: Haberecker, Martina, et al.
Publicado: (2022)

Where is genomics going next?
por: Cheifet, Barbara
Publicado: (2019)

SMARCB1-deficient sinonasal carcinoma: a case report and literature review
por: Yanagawa, Naoki, et al.
Publicado: (2021)

Orbital Apex Syndrome Secondary to SMARCB1-Deficient Invasive Sinonasal Carcinoma
por: Massey, Denzel, et al.
Publicado: (2022)

Underreporting of SMARCB1 alteration by clinical sequencing: Integrative patho-genomic analysis captured SMARCB1/INI-1 deficiency in a vulvar yolk sac tumor
por: Wei, Christina H., et al.
Publicado: (2023)

Where do we look for the next breakthrough in sleep research?
por: Viganò, Alessandro, et al.
Publicado: (2023)

NICE verdict on Temozolomide: where next?
por: Brada, M
Publicado: (2002)

Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2
por: Sarkar, Sanila, et al.
Publicado: (2023)

Fulminant presentation of a SMARCB1-deficient, anterior cranial fossa tumor in adult
por: Levitan, Idan, et al.
Publicado: (2020)

SMARCB1‐deficient basal cell carcinoma of the prostate controlled using radiation therapy
por: Makabe, Shunta, et al.
Publicado: (2023)

Inhibition of MYC by the SMARCB1 tumor suppressor
por: Weissmiller, April M., et al.
Publicado: (2019)

Where Do Omics and Markers Go Next?
por: Sharp, Frank R.
Publicado: (2010)

Traditional Medicines in the World: Where to Go Next?
por: Pan, Si-Yuan, et al.
Publicado: (2014)

Immunotherapy failure in adrenocortical cancer: where next?
por: Cosentini, Deborah, et al.
Publicado: (2018)

Air pollution and children’s health: where next?
por: Whitehouse, Abigail, et al.
Publicado: (2021)

CHIPped balance of proteostasis and longevity
por: Pokrzywa, Wojciech, et al.
Publicado: (2017)

Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5
por: Li, Mingxuan, et al.
Publicado: (2021)

Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
por: Florian, Andrea C, et al.
Publicado: (2022)

Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells
por: Darr, Jonatan, et al.
Publicado: (2015)

SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors
por: Liu, Ning Qing, et al.
Publicado: (2023)

Malignant rhabdoid tumor of the kidney in an adult with loss of INI1 expression and mutation in the SMARCB1 gene
por: Han, Eunkyung, et al.
Publicado: (2021)

SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance
por: Vokshi, Bujamin H., et al.
Publicado: (2023)

Redox Status and Proteostasis in Ageing and Disease
por: Rizzi, Federica, et al.
Publicado: (2016)

The Role of Proteostasis Derailment in Cardiac Diseases
por: Brundel, Bianca J. J. M.
Publicado: (2020)

Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers
por: Richer, Wilfrid, et al.
Publicado: (2017)

Erratum to: ‘Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells’
por: Darr, Jonatan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tg1cj7hk91ai92qsvt65kkr7ri